ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Cardiac effects of one-year levetiracetam monotherapy in children with genetic generalized epilepsy: a prospective longitudinal study.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEpilepsy has been associated with alterations in cardiac repolarization, and the potential cardiac effects of antiseizure medications have raised increasing clinical interest. However, longitudinal pediatric data evaluating cardiac parameters during levetiracetam monotherapy remain limited. We aimed to prospectively assess electrocardiographic and echocardiographic changes during one year of levetiracetam monotherapy in children with genetic generalized epilepsy.
methodsThis prospective study included 52 children with newly diagnosed genetic generalized epilepsy, with generalized tonic-clonic seizures alone, receiving levetiracetam monotherapy. Standard 12-lead electrocardiography and transthoracic echocardiography were performed at baseline and after one year. Electrocardiographic parameters included PR, QTc, Tpeak-Tend (Tp-e), and Tp-e-based ratios. Echocardiographic measurements were analyzed using age- and body size-adjusted Z-scores.
resultsFifty-two patients (mean age 9.31 ± 4.49 years; 42.3% female) completed follow-up. No statistically significant differences were observed between baseline and one-year electrocardiographic parameters, including PR (p = 0.725), QTc (399.80 ± 15.84 vs. 396.44 ± 20.00 ms; p = 0.143), Tp-e (p = 0.070), Tp-e/QT (p = 0.753), and Tp-e/QTc (p = 0.370). Echocardiographic indices, including LVDd Z-score (p = 0.535), IVSd Z-score (p = 0.099), and ejection fraction (68.13 ± 3.87% vs. 68.25 ± 3.86%; p = 0.666), showed no longitudinal changes.
conclusionsIn this prospective pediatric cohort of children with genetic generalized epilepsy, one year of levetiracetam monotherapy was not associated with adverse electrocardiographic or echocardiographic changes. These findings support a favorable cardiac safety profile of levetiracetam during one year of monotherapy in this pediatric population.
Indexed as
Identifiers
42315704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.